인실리코 임상시험 시장 규모, 점유율, 성장 분석 : 전개 모델별, 시험 단계별, 용도별, 치료 분야별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global In Silico Clinical Trials Market size was valued at USD 4.2 Billion in 2024 and is poised to grow from USD 4.49 Billion in 2025 to USD 7.66 Billion by 2033, growing at a CAGR of 6.9% during the forecast period (2026-2033).

The in silico clinical trials market is primarily fueled by advances in computational modeling, increasing regulatory acceptance, and the urgent need to minimize drug development costs and timelines. By employing computer simulations and digital twins, in silico trials enhance predictions of safety and efficacy, serving as both alternative and complementary approaches to traditional methods. This innovative approach reduces patient risk, expedites approvals, and facilitates studies within hard-to-recruit vulnerable populations. With the ongoing evolution from basic pharmacokinetic modeling to sophisticated multiscale simulations, supported by improved computational power and machine learning, industry stakeholders are witnessing greater confidence in predictive models. As AI further transforms patient representation and trial optimization, the market is set to thrive, presenting numerous opportunities across various sectors, including device manufacturing and oncology.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global In Silico Clinical Trials market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global In Silico Clinical Trials Market Segments Analysis

Global in silico clinical trials market is segmented by deployment model, trial phase, application, therapeutic area, end user and region. Based on deployment model, the market is segmented into Cloud-Based Platforms, On-Premises Platforms and Hybrid Platforms. Based on trial phase, the market is segmented into Preclinical Trials, Phase I Trials, Phase II Trials, Phase III Trials and Phase IV / Post-Market Studies. Based on application, the market is segmented into Drug Development, Medical Device Development, Personalized Medicine, Disease Modeling, Toxicology Testing, Clinical Trial Optimization and Regulatory Submission & Validation. Based on therapeutic area, the market is segmented into Oncology, Cardiovascular Diseases, Neurology, Infectious Diseases, Metabolic Disorders, Respiratory Diseases, Orthopedics, Rare Diseases and Others. Based on end user, the market is segmented into Pharmaceutical Companies, Biotechnology Companies, Medical Device Manufacturers, Contract Research Organizations (CROs), Academic & Research Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global In Silico Clinical Trials Market

One of the key market drivers for the global in silico clinical trials market is the increasing demand for cost-effective and efficient drug development processes. In silico trials leverage advanced computational models and simulations to predict the effectiveness and safety of new therapeutics, significantly reducing the time and resources spent on traditional clinical trials. Additionally, the pressure to comply with stringent regulatory requirements and the need for personalized medicine approaches further propel the popularity of in silico trials. These factors collectively contribute to a transformative shift in how clinical research is conducted, enhancing innovation and reducing the burden on healthcare systems.

Restraints in the Global In Silico Clinical Trials Market

One of the key market restraints for the global in silico clinical trials market is the regulatory uncertainty surrounding the acceptance of computational models and simulations by regulatory agencies. As the technology evolves, there may be a lag in the establishment of guidelines and standards that govern its use, leading to hesitancy among pharmaceutical companies and research institutions to fully integrate in silico trials into their development pipelines. Additionally, concerns regarding the accuracy and reliability of computational predictions can hinder broader adoption, as stakeholders demand substantial validation and evidence before committing resources to this innovative approach.

Market Trends of the Global In Silico Clinical Trials Market

The Global In Silico Clinical Trials market is witnessing a transformative shift towards AI-driven personalized simulations, propelled by the adoption of cutting-edge machine learning and mechanistic modeling techniques. This evolution enables the creation of individualized virtual patients that embody a range of physiological and disease pathways, fostering adaptive protocol design. As stakeholders increasingly prioritize models that reflect patient heterogeneity, the ability to identify likely responders and nonresponders early on not only streamlines trial processes but also enhances predictive accuracy for biomarker selection and dosing strategies. This trend is reducing the need for costly trial iterations while bolstering translational confidence and improving overall decision-making efficiency across various stages of drug development.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global In Silico Clinical Trials Market Size by Deployment Model & CAGR (2026-2033)

• Market Overview
• Cloud-Based Platforms
• On-Premises Platforms
• Hybrid Platforms

Global In Silico Clinical Trials Market Size by Trial Phase & CAGR (2026-2033)

• Market Overview
• Preclinical Trials
• Phase I Trials
• Phase II Trials
• Phase III Trials
• Phase IV / Post-Market Studies

Global In Silico Clinical Trials Market Size by Application & CAGR (2026-2033)

• Market Overview
• Drug Development
• Medical Device Development
• Personalized Medicine
• Disease Modeling
• Toxicology Testing
• Clinical Trial Optimization
• Regulatory Submission & Validation

Global In Silico Clinical Trials Market Size by Therapeutic Area & CAGR (2026-2033)

• Market Overview
• Oncology
• Cardiovascular Diseases
• Neurology
• Infectious Diseases
• Metabolic Disorders
• Respiratory Diseases
• Orthopedics
• Rare Diseases
• Others

Global In Silico Clinical Trials Market Size by End User & CAGR (2026-2033)

• Market Overview
• Pharmaceutical Companies
• Biotechnology Companies
• Medical Device Manufacturers
• Contract Research Organizations (CROs)
• Academic & Research Institutes
• Others

Global In Silico Clinical Trials Market Size & CAGR (2026-2033)

• North America (Deployment Model, Trial Phase, Application, Therapeutic Area, End User)
  • US
  • Canada
• Europe (Deployment Model, Trial Phase, Application, Therapeutic Area, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Deployment Model, Trial Phase, Application, Therapeutic Area, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Deployment Model, Trial Phase, Application, Therapeutic Area, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Deployment Model, Trial Phase, Application, Therapeutic Area, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Dassault Systemes
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ansys
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Simulations Plus
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Certara
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insilico Medicine
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• InSilicoTrials Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aetion
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Physiomics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novadiscovery
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rosa & Co.\ LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immunetrics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genedata
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ELEM Biotech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Applied Biomath
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biomax Informatics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• HeartFlow
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Numerate
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cyclica
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evotec
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qure.ai
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations